Physician profile
Mark S Rosenberg
NPI 1851459390
$2,142.74
in general payments reported to CMS, 2019-2025
19 companies · $423 in 2025
The $423 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2021: $296 · 2022: $320 · 2023: $353 · 2024: $569 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $399.95 | 2019-2025 | Coroflow, Triclip |
| Ancora Heart, INC. | $178.27 | 2025 | Accucinch |
| Lexicon Pharmaceuticals, INC. | $162.69 | 2023-2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $161.33 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $159.70 | 2021 | |
| Abiomed | $145.69 | 2023 | Impella |
| Esperion Therapeutics, INC. | $130.65 | 2022-2025 | Nexletol |
| Medtronic, INC. | $128.43 | 2024 | Symplicity G3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.57 | 2022-2024 | Lifevest |
| United Therapeutics Corporation | $114.75 | 2024 | |
| Pfizer INC. | $107.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $105.79 | 2021-2022 | |
| Amgen INC. | $103.68 | 2023-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $40.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.12 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21.95 | 2022 | |
| Irhythm Technologies, INC. | $15.65 | 2024 | Zio Xt Patch |
| Kiniksa Pharmaceuticals International, Plc | $14.40 | 2024 | Arcalyst |
| Genzyme Corporation | $14.16 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.